BioSpace News Archive

Spago Nanomedical AB announced that the company has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis - a chronic, debilitating condition that affects up to 10 percent of women of reproductive age.

ADAMA Ltd., a leading global crop protection company, announced the acquisition of AgriNova New Zealand, Ltd – known as Grochem New Zealand.

Mainz Biomed NV announced that it has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.

AMO Pharma Limited announced completion of patient enrollment in the company’s REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.

ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.

AlzeCure Pharma AB announced that the subscription period in the Company’s capital raising begins December 06 and runs until December 20, 2022.

Natera, Inc., a global leader in cell-free DNA testing, announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide polymorphism -based noninvasive prenatal test.

Achilles Therapeutics plc today presented an encouraging interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma at the ESMO Immuno-Oncology Congress 2022 (ESMO IO).

Celldex Therapeutics, Inc. today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GA²LEN Global Urticaria Forum (GUF) held in Berlin, Germany.

Acutus Medical, Inc. today announced receipt of a CE Mark issued under the European Union (EU) Medical Device Regulations (MDR) for its AcQMap 3D Imaging and Mapping Catheter, the world’s only integrated high-resolution ultrasound imaging and non-contact mapping catheter.